Polygonal Area of Prosthesis Support with Straight and Tilted Dental Implants in Edentulous Maxillae.

PURPOSE: The aim of this in vitro study was to assess the increase in the polygonal area of implant-retained prosthesis supports in edentulous maxillae with the use of tilted distal implants compared with the use of straight distal implants, using a variety of implant lengths. MATERIALS AND METHODS: A total of 25 DICOM datasets of atrophic edentulous maxillae were provided. Bone augmentations in the molar region had to be avoided. Two straight reference implants were virtually inserted in the anterior region. Two additional implants were placed far distally on both sides (4 groups: [1] straight, 12-mm length; [2] straight, 10 mm; [3] straight, 8 mm; [4] tilted, 12-16 mm). The resulting implant-supported polygon was measured for each of the 4 groups using three-dimensional planning software. RESULTS: The mean sagittal depth of the supported polygon in Group 1 was 9.9 mm (standard deviation [SD] 4.4) on the right and 10.2 mm (SD 4.4) on the left, and it was 33.7 mm (SD 5.8) in width. For Group 2, the mean sagittal depth was 11.5 mm (SD 5.0) on the right and 11.9 mm (SD 4.7) on the left, and the width was 35.2 mm (SD 5.6). The measurements for Group 3 were 13.8 mm (SD 4.9) deep on the right, 13.8 mm (SD 5.1) deep on the left, and 37.0 mm (SD 5.4) in width. For Group 4, the depth was 15.8 mm (SD 4.9) on the right and 16.4 mm (SD 5.8) on the left, and the width was 39.0 mm (SD 5.1). CONCLUSION: The area of implant-retained prosthesis support can be enlarged by the use of tilted implants (12 to 16 mm in length, 42 to 45 degrees) compared to the use of straight 8-mm implants (resulting increase: about 15%).

Fracture Strength of Monolithic All-Ceramic Crowns on Titanium Implant Abutments.

PURPOSE: The fracture strengths of all-ceramic crowns cemented on titanium implant abutments may vary depending on crown materials and luting agents. The purpose of this study was to examine differences in fracture strength among crowns cemented on implant abutments using crowns made of seven different monolithic ceramic materials and five different luting agents. MATERIALS AND METHODS: In total, 525 crowns (75 each of Vita Mark II, feldspathic ceramic [FSC]; Ivoclar Empress CAD, leucite-reinforced glass ceramic [LrGC]; Ivoclar e.max CAD, lithium disilicate [LiDS]; Vita Suprinity, presintered zirconia-reinforced lithium silicate ceramic [PSZirLS]; Vita Enamic, polymer-reinforced fine-structure feldspathic ceramic [PolyFSP], Lava Ultimate; resin nanoceramic [ResNC], Celtra Duo; fully crystallized zirconia-reinforced lithium silicate [FcZirLS]) were milled using a CAD/CAM system. The inner surfaces of the crowns were etched and silanized. Titanium implant abutments were fixed on implant analogs, and airborne-particle abrasion was used on their exterior specific adhesion surfaces (Al2O3, 50 µm). Then, the abutments were degreased and silanized. The crowns were cemented on the implant abutments using five luting agents (Multilink Implant, Variolink II, RelyX Unicem, GC FujiCEM, Panavia 2.0). After thermocycling for 5,000 cycles (5 to 55°C, 30 seconds dwell time), the crowns were subjected to fracture strength testing under static load using a universal testing machine. Statistical analyses were performed using analysis of variance (α = .0002) and the Bonferroni correction. RESULTS: No significant difference among the luting agents was found using the different all-ceramic materials. Ceramic materials LiDS, PSZirLS, PolyFSP, and ResNC showed significantly higher fracture strength values compared with FSC, FcZirLS, and LrGC. The PSZirLS especially showed significantly better results. CONCLUSION: Within the limitations of this study, fracture strength was not differentially affected by the various luting agents. However, the fracture strength was significantly higher for PSZirLS, PolyFSP, ResNC, and LiDS ceramics than for the FSP, LrGC, and the FcZirLS ceramic with all luting agents tested.

Sensitivity and Specificity of Stability Criteria for Immediately Loaded Splinted Maxillary Implants.

BACKGROUND: To assess the suitability of dental implants for immediate loading, primary stability is usually evaluated intraoperatively. PURPOSE: This retrospective study aimed to assess the suitability of three stability parameters - namely, insertion torque (IT), implant stability quotient (ISQ; measured by resonance frequency analysis), and Periotest (PT) values - as potential predictors for the risk of nonosseointegration of immediately loaded splinted implants. The stability parameters were routinely collected under immediate loading. MATERIALS AND METHODS: Nineteen patients with 11 edentulous and 8 partially edentulous maxillae were treated with 105 dental implants, which were immediately loaded using temporary fixed dentures. The IT results, PT values, and ISQ results were recorded. Receiver operating characteristic analysis was performed to assess the quality of each parameter as a diagnostic test. RESULTS: After a 3-month observation period, 11 implants in four patients were not osseointegrated. The IT and ISQ (IT 25.0 ± 12.5 Ncm and 8.4 ± 2.3 Ncm; PT -1.5 ± 3.0 and +2.7 ± 3.0; and ISQ 62.6 ± 6.7 and 54.7 ± 6.2) differed significantly between the osseointegrated and failed implants (p < .005). The IT showed the greatest specificity at a sensitivity of 1 and the greatest area under the curve (AUC; 0.929), followed by the PT value (AUC = 0.836) and ISQ (AUC = 0.811). CONCLUSIONS: Among the intraoperative parameters analyzed, IT showed the highest specificity at a high sensitivity of 1. Therefore, the IT can be considered the most valid prognostic factor for osseointegration of immediately loaded splinted dental implants.

Retentive strength of monolithic all-ceramic crowns on implant abutments.

The aim of the study was to determine the retentive strength of monolithic all-ceramic crowns cemented on titanium implant abutments. 225 crowns (75 crowns each of Mark II, Empress CAD, and e.max CAD) were milled using a CAD/ CAM system. The crowns were cemented onto sandblasted titanium implant abutments using five luting agents (Multilink Implant, Variolink II, RelyX Unicem, Fujicem, and Panavia 2.0). After thermocycling, the crowns were removed using a universal testing machine. The location of luting agent residue on the abutment and inner crown surfaces was evaluated. Statistical analysis was performed using ANOVA with the Bonferroni correction. In comparing the luting agents, no significant difference was found between Vita Mark II and Empress CAD. For e.max CAD, the luting agent RelyX Unicem had a significantly higher mean retentive strength than did Multilink Implant (p = 0.003) or Panavia 2.0 (p = 0.001). In comparing the ceramic materials, e.max CAD showed significantly higher pull-off strengths than the other two ceramic materials when the luting agents RelyX Unicem and Fujicem were used (all p < 0.001). The residues of nearly all luting agents were located entirely or almost entirely (75%-100%) on the inner crown surfaces of all ceramic materials, except for the luting agent GC Fujicem, which left more luting agent residue (0%-75%) on the abutment surfaces of all ceramic materials. In comparing the five luting agents, significant differences in the resulting retentive strength were only found for the ceramic material e.max CAD. The other ceramic materials did not show significant differences in retentive strength, independent of the luting agent.

Bone healing with or without platelet-rich plasma around four different dental implant surfaces in beagle dogs.

PURPOSE: Surface development is one of the major aims in dental implant engineering. Additive application of substances could possibly improve the new bone formation around dental implants. The present study evaluated the bone reaction on four different implant surfaces with or without platelet-rich plasma (PRP). MATERIALS AND METHODS: Four self-tapping titanium screw implants (Brånemark MK III [Nobel Biocare, Göteborg, Sweden], Osseotite [3i, Miami, FL, USA], Xive [Densply Friadent, Mannheim, Germany], and Compress [IGfZ eG, Diez, Germany]) with different surfaces were inserted in each hemimandible of 12 female beagle dogs; the implant positions and the application of PRP were randomized. After intravital fluorochrome staining, sacrifices and biopsies harvesting were performed after 6 weeks (five dogs; one dog died before) and 12 weeks (six dogs) and the respective specimens were analyzed. RESULTS: The only significant difference in bone remodeling was found for the Compress implants with increased bone formation compared with the Brånemark implants at 12 weeks (sign test, p = .03). Comparing the histological and histomorphometric specimens of all other implant surfaces with respect to peri-implant bone remodeling and the resulting bone-implant contact rates (BICRs), no statistically significant differences were seen in the PRP or non-PRP groups (sign test, all p values ≥ .063). CONCLUSIONS: This study found no significant differences in the BICR for roughened implant surfaces compared with machined surfaces. In this animal model, the addition of PRP did not demonstrate evidence of faster bone formation or the resulting BICR.

Comparison of point-of-care methods for preparation of platelet concentrate (platelet-rich plasma).

PURPOSE: This study analyzed the concentrations of platelets and growth factors in platelet-rich plasma (PRP), which are likely to depend on the method used for its production. MATERIALS AND METHODS: The cellular composition and growth factor content of platelet concentrates (platelet-rich plasma) produced by six different procedures were quantitatively analyzed and compared. Platelet and leukocyte counts were determined on an automatic cell counter, and analysis of growth factors was performed using enzyme-linked immunosorbent assay. RESULTS: The principal differences between the analyzed PRP production methods (blood bank method of intermittent flow centrifuge system/platelet apheresis and by the five point-of-care methods) and the resulting platelet concentrates were evaluated with regard to resulting platelet, leukocyte, and growth factor levels. The platelet counts in both whole blood and PRP were generally higher in women than in men; no differences were observed with regard to age. Statistical analysis of platelet-derived growth factor AB (PDGF-AB) and transforming growth factor ß1 (TGF-ß1) showed no differences with regard to age or gender. Platelet counts and TGF-ß1 concentration correlated closely, as did platelet counts and PDGF-AB levels. There were only rare correlations between leukocyte counts and PDGF-AB levels, but comparison of leukocyte counts and PDGF-AB levels demonstrated certain parallel tendencies. CONCLUSIONS: TGF-ß1 levels derive in substantial part from platelets and emphasize the role of leukocytes, in addition to that of platelets, as a source of growth factors in PRP. All methods of producing PRP showed high variability in platelet counts and growth factor levels. The highest growth factor levels were found in the PRP prepared using the Platelet Concentrate Collection System manufactured by Biomet 3i.

Effect of preparation depth differences on the marginal fit of zirconia crown copings: an in vitro study.

If optical scanning is used for crown fabrication, variability in preparation depth may be a limitation. Therefore, this preliminary laboratory study evaluated marginal fit in relation to preparation depth. Three dies with different preparation depths between the vestibular and oral regions were fabricated. Ten zirconia copings were manufactured for each die, and marginal gaps were examined. Increasing differences in preparation depth influenced the size of the marginal gap between the vestibulo-oral and mesiodistal regions significantly (P < .001). This study shows primarily that differences in preparation depth resulted in decreasing marginal precision.

The influence of PRP on early bone formation in membrane protected defects. A histological and histomorphometric study in the rabbit calvaria.

BACKGROUND: Platelet rich plasma (PRP) has been proposed to be a useful adjunct to bone grafting. PURPOSE: The aim of the present study was to assess new bone formation in bone regeneration procedures using platelet rich plasma (PRP) alone or in combination with autogenous bone. MATERIALS AND METHODS: Four surgically created, monocortical defects 5 mm in diameter in the calvariae of 15 New Zealand rabbits were grafted with a coagulum-filled control, PRP, particulated autogenous bone alone (A), or combined with PRP (A-PRP). RESULTS: Mean platelet concentration of 1,761,930 ± 680,200/µl was achieved (5.30 ± 2.63 × fold of baseline). Animals were sacrificed 1, 2, and 4 weeks later. Histomorphometric analysis showed no statistical difference for total new bone formation at any time point, however, a detailed analysis revealed a statistically significant higher percentage of lamellar bone than woven bone for the autogenous bone group at 2 weeks; all other groups demonstrated equal percentages of either bone type. At 4 weeks, all groups revealed a statistically greater component of lamellar bone over woven bone. Graft resorption rate was similar for both A and A-PRP. PRP platelet concentration was significantly positively correlated with TGF-beta1 but not with PDGF-AB. CONCLUSIONS: Within the limits of the chosen animal model, this study demonstrated that PRP during early healing, whether alone or mixed with autogenous bone, did not lead to greater bone remodelling, as compared to coagulum. In contrast, autogenous bone alone demonstrated accelerated bone remodelling at 2 weeks.

Clinical report with up to 4 years of follow-up on a cervically modified stepped screw-type implant.

PURPOSE: In 1998, a modification of the macrostructure of the Frialit-2 implant in the cervical region was introduced to stabilize peri-implant bone. Limited data are available on the clinical effect of this modification. Therefore, the soft-tissue situation, marginal bone loss, and implant failure rate were analyzed after 4 years of clinical experience with the modified Frialit-2 Synchro implant. MATERIALS AND METHODS: From 1998 to 2001, 190 cervically modified implants were placed and documented prospectively in 58 patients. Of these implants, 147 were placed in original jaw bone, 22 in areas augmented with local osteoplasty, and 21 in iliac crest bone graft. The main indications for implantation were an atrophic edentulous alveolar crest (n = 99) and support for a partial denture (n = 39), followed by restoration of a shortened dental arch (n = 28) and single tooth replacement (n = 24). In a special clinical examination, 39 patients with 134 implants were investigated. RESULTS: The average in situ time of the 134 implants was 23.1 months. Failing osseointegration (n = 10), peri-implantitis (n = 1), and tumor resection (n = 3) in 8 patients resulted in the failure of 14 of 190 implants (7.4%). One patient with 4 implants died (2.1%). Currently, 3 patients with a total of 6 implants have been lost to follow-up (3.1%), and 166 implants remain in situ (87.4% of 190). DISCUSSION: Using different implant success criteria, success rates of 88.8% and 82.8% were calculated. CONCLUSION: Based on the results, the Frialit-2 Synchro implant appears to be a useful implant system for the indications analyzed.

Platelet-rich plasma and platelet gel: a review.

Strategies to reduce blood loss and transfusion of allogeneic blood products during surgical procedures are important in modern times. The most important and well-known autologous techniques are preoperative autologous predonation, hemodilution, perioperative red cell salvage, postoperative wound blood autotransfusion, and pharmacologic modulation of the hemostatic process. At present, new developments in the preparation of preoperative autologous blood component therapy by whole blood platelet-rich plasma (PRP) and platelet-poor plasma (PPP) sequestration have evolved. This technique has been proven to reduce the number of allogeneic blood transfusions during open heart surgery and orthopedic operations. Moreover, platelet gel and fibrin sealant derived from PRP and PPP mixed with thrombin, respectively, can be exogenously applied to tissues to promote wound healing, bone growth, and tissue sealing. However, to our disappointment, not many well-designed scientific studies are available, and many anecdotic stories exist, whereas questions remain to be answered. We therefore decided to study perioperative blood management in more detail with emphasis on the application and production of autologous platelet gel and the use of fibrin sealant. This review addresses a large variety of aspects relevant to platelets, platelet-rich plasma, and the application of platelet gel. In addition, an overview of recent animal and human studies is presented.

Bone regeneration in standardized bone defects with autografts or bone substitutes in combination with platelet concentrate: a histologic and histomorphometric study in the mandibles of minipigs.

PURPOSE: To evaluate the effect of the addition of platelet concentrate (PC) to autografts or bone substitutes on bone regeneration in standardized bone defects. MATERIALS AND METHODS: Three standardized bone defects were prepared in both mandibular angles of 12 adult minipigs. The defects were grafted with autograft, anorganic bovine bone, or synthetic beta-tricalcium phosphate (beta-TCP). PC was added to only 1 side. The animals were divided into 4 groups, which were sacrificed at 4 different time points (1, 2, 4, and 8 weeks) for histologic and histomorphometric analysis. The concentrations of platelets and growth factors were measured to identify correlation to the histologic and histomorphometric results. RESULTS: No correlation was found between platelet count in whole blood and platelet count in PC (r(p) = 0.36). Furthermore, no correlation could be demonstrated between the platelet count of the PC and the concentrations of PDGF-AB (r(p) = -0.27) and TGF-beta (r(p) = 0.34). There were no signs of a stimulating effect of PC on bone formation in combination with autografts or bone substitutes at any time point (P = .89). Addition of PC did not alter the pattern of graft degradation. DISCUSSION: The present study underlines the need for further investigation to identify the optimal concentrations of platelets and combinations of growth factors to achieve a predictable stimulatory effect on bone regeneration. One of the first steps to achieve this goal will be the development of a reliable method for the procurement of PC. CONCLUSION: PC had no impact on bone formation and graft degradation in standardized bone defects in the mandibles of minipigs.

Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: a technical report.

PURPOSE: The aim of this study was to compare a new method for the production of platelet-rich plasma (PRP), the plasma-rich-in-growth-factors kit (PRGF kit; G.A.C. Medicale San Antonio, Vitoria, Spain), with an established method, the Platelet Concentrate Collection System (PCCS; 3i/Implant Innovations, Palm Beach Gardens, FL) with respect to resulting cellular and growth factor contents. MATERIALS AND METHODS: Whole blood was drawn from 51 healthy donors (20 men, 31 women) aged 19 to 59 years (mean +/- SD 35.12 +/- 9.65 years), and PRP was prepared by both methods. RESULTS: Platelet counts differed significantly (signed rank test, P < .001 for all) between the donor blood (274,200 +/- 54,050/microL), the PCCS PRP preparation (1,641,800 +/- 426,820/microL), and the PRGF kit PRP preparation (513,630 +/- 139,470/microL). The PCCS concentrated leukocytes (whole blood, 6,992 +/- 2,011/microL; PCCS PRP, 14,153 +/- 7,577/microL), while the PRGF kit produced a leukocyte-poor PRP (65 +/- 108/microL). Higher concentrations of transforming growth factor beta1 (TGF-beta1) and platelet-derived growth factor AB (PDGF-AB) were found in the PCCS PRP (TGF-/beta1, 290 +/- 95 ng/mL; PDGF-AB, 157 +/- 62 ng/mL) than in the Anitua PRGF kit PRP (TGF-beta1, 73 +/- 26 ng/mL; PDGF-AB, 47 +/- 21 ng/mL). Statistical analysis showed significant differences (P < .001 for TGF-beta1 and P < .01 for PDGF-AB). DISCUSSION: The results of this study and some data in the literature indicate that the content of growth factors in PRP can vary tremendously, depending on the system used for the preparation of PRP. CONCLUSION: PCCS collects more platelets and leukocytes than the PRGF kit. This results in significantly higher growth factor levels. Further in vivo studies are needed to determine whether this results in a clinically different biologic effect.

Comparison of platelet, leukocyte, and growth factor levels in point-of-care platelet-enriched plasma, prepared using a modified Curasan kit, with preparations received from a local blood bank.

The potential use of autologous thrombocytic growth factors to accelerate bone regeneration requires improved methods of isolating platelet-rich plasma (PRP). In addition to discontinuous cell separation, a second method by which PRP is produced at the point-of-care has now become available. In this study, growth factor levels in PRP from these two sources were compared. Whole blood was drawn from 115 healthy donors (73 males, 42 females) aged 21 - 62 years (mean 36, SD 10). The PRP was separated by the blood bank (BB) using the discontinuous cell separation method or at the 'point-of-care' by the so-called 'buffy coat' method (analogous to the Curasan PRP Kit). Growth factor content differed significantly for TGF-beta1 (BB 268.65+/-70.77 ng/ml, Curasan 95.02+/-60.67 ng/ml (sign test P<0.001)) and PDGF-AB (BB 133.59+/-46.26 ng/ml, Curasan 233.70+/-111.86 ng/ml (P<0.001)), while the content of IGF-I (BB 85.37+/-25.58 ng/ml, Curasan 101.72+/-47.7 ng/ml (P<0.160)) showed no significant difference. The higher thrombocyte count in the BB PRP (BB 1434300+/-351960/ microl, Curasan 908.500+/-492.30/microl) seems to result in higher TGF-beta1 levels, while the higher leukocyte count in the Curasan PRP (BB 160+/-320/ microl, Curasan 30130+/-12500/microl) seems to result in higher PDGF-AB levels. The similar IGF-I levels in the two preparations might merely reflect similar amounts of plasma in the PRP produced by each approach.

The Harvest Smart PRePTM system versus the Friadent-Schütze platelet-rich plasma kit.

An important reason to improve methods for isolating platelet-rich plasma (PRP) is the potential use of autogenous platelet growth factors. In addition to the Curasan PRP kit (Curasan, Kleinostheim, Germany) and the platelet concentrated collection system (PCCSTM) system, two new methods for the preparation of PRP by the surgeon are now available. This study compared the suitability of these new methods for the preparation of PRP. Whole blood was drawn from 54 healthy donors (33 men and 21 women) aged 23-79 years (38.0 +/- 17.7 years). PRP was prepared from each donor's blood using both the Smart PRePTM system (Harvest Technologies Corporation, Munich, Germany) and the Friadent-Schütze method (PRP kit; Friadent-Schütze, Vienna, Austria). The platelet count in donor whole blood was 276 810 +/- 59 440 /microl. Platelet counts differed significantly between the Smart PRP preparation (1227 890 +/- 312 440 platelets/microl) and the Friadent-Schütze PRP preparation (1440 500 +/- 501 700 platelets/microl) (sign test, P < 0.001). The Smart PRePTM system had a significantly higher collection efficiency (63.4 +/- 7.9%) than the Friadent-Schütze kit (49.6 +/- 13.6%) (sign test, P < 0.001). The leukocyte contents in the two platelet concentrates were similar (Smart PRePTM, 19 261 +/- 8082 platelets/microl; Friadent-Schütze, 21 691 +/- 16 430). Transforming growth factor (TGF)-beta1 and platelet-derived growth factor (PDGF)-AB were higher in the Friadent-Schütze PRP (TGF-beta1, 196.8 +/- 109.6 ng/ml; PDGF-AB, 251.6 +/- 115.4 ng/ml) than in the Smart PRePTM (TGF-beta1, 77.2 +/- 54.8 ng/ml; PDGF-AB, 208 +/- 85.2 ng/ml). The sign test indicated significant differences between the two methods in the concentrations of TGF-beta1 (P < 0.001) and PDGF-AB (P < 0.01). Insulin-like growth factor (IGF)-1 levels in the two PRP preparations were similar (Friadent-Schütze PRP, 72.8 +/- 22.3 ng/ml; Smart PRePTM, 91.4 +/- 21.3 ng/ml). The Smart PRePTM system was superior with respect to ease of handling and preparation time. It also had a significantly higher platelet collection efficiency than the Friadent-Schütze PRePTM kit. The Friadent-Schütze PRP kit offers a slight advantage in the resulting PRP platelet concentration. However, this is easily compensated for in the Smart PRePTM system by reducing the volume of the resulting PRP.

Curasan PRP kit vs. PCCS PRP system. Collection efficiency and platelet counts of two different methods for the preparation of platelet-rich plasma.

An important reason to improve methods of isolating platelet-rich plasma (PRP) is the potential use of autologous thrombocyte growth factors. In addition to discontinuous cell separation, two methods for extracting PRP that can be performed directly by the surgeon are now available. This study compared the suitability of these two methods for the preparation of PRP. Whole blood was drawn from 47 healthy donors (18 men, 29 women) aged 20-59 years (mean 29.9, SD 7.7). For each donor, PRP was separated by the PCCS method (PCCS Kit, 3i Implant Innovations, Palm Beach Gardens, FL, USA) and by the Curasan method (analogous to the PRP kit, Curasan, Kleinostheim, Germany). Thrombocyte counts differed significantly (sign test P = 0.001) between the donor blood (mean 290,000/ micro l, SD 86,000/ microl), the PCCS PRP preparation (mean 2,209,000/ microl, SD 901,000/ microl), and the Curasan PRP (mean 1,075,000/ micro l, SD 636,000/ microl). The correlation between the thrombocyte count in the PRP and the thrombocyte count in the donor whole blood was greater for the PCCS PRP (Spearman's correlation coefficient rS = 0.60) than for the Curasan PRP (r(S) = 0.34). A slight, clinically irrelevant, influence of gender on thrombocyte concentration in whole blood was found, but no influence of age was detected.

Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count.

INTRODUCTION: Platelet-rich plasma contains autologous thrombocyte growth factors and might be promising for acceleration of dentoalveolar bone regeneration. In this study, it was analysed for platelet counts and growth factor concentrations. MATERIAL AND METHOD: Platelet-rich plasma was isolated by discontinuous cell separation from 158 healthy men and 55 women aged 17-62 years. One hundred and fifteen specimens (stratified for age and gender of the donor) were analysed for growth factor concentrations and platelet count. RESULTS: The platelet count in platelet-rich plasma (1,407,640+/-320,100/microl) was 5 times higher than in donor blood (266,040+/-60,530/microl). Platelet-derived growth factor AB (117+/-63 ng/ml), transforming growth factor (TGF) beta -1 (169+/-84 ng/ml), and insulin-like growth factor (IGF) I (84+/-23 ng/ml) were found in large amounts, while platelet-derived growth factor (PDGF) BB (10+/-8 ng/ml) and transforming growth factor beta -2 (0.4+/-0.3 ng/ml) were found in small amounts only. The growth factor content was not well correlated with the platelet count in whole blood nor with the platelet-rich plasma (r(p)=0.35). No influence of gender or age on platelet count or growth factor concentrations was discovered (except IGF-I). CONCLUSIONS: While there was substantial variation in the growth factor content of platelet-rich plasma, the factors influencing this are still worthy of further investigation. Furthermore, a technique whereby the growth factor content could be rapidly assessed in platelet-rich plasma may be of therapeutic benefit.

Growth factor levels in the platelet-rich plasma produced by 2 different methods: curasan-type PRP kit versus PCCS PRP system.

PURPOSE: Potential treatments using autologous thrombocyte growth factors are an important reason to improve methods for isolating platelet-rich plasma (PRP). Two methods for extracting PRP directly by the surgeon are currently available; this study was conducted to compare the growth factor levels in the resulting PRP. MATERIALS AND METHODS: Whole blood was drawn from 46 healthy donors (17 men, 29 women) aged 20 to 59 years (29.9 +/- 7.8). PRP was then separated from each sample by both the PCCS (3i) and Curasan (PRP Kit, Curasan) methods. RESULTS: The growth factor content differed significantly for TGF-beta1 (PCCS 467.1 ng/mL; Curasan 79.7 ng/mL) (sign test P < .0001) and PDGF-AB (PCCS 251.8 ng/mL; Curasan 314.1 ng/mL) (P < .0001); this was less significant for IGF-I (PCCS 91.0 ng//mL; Curasan 69.5 ng/mL) (P < .02). The higher platelet count in the PCCS PRP (PCCS 2,232,500/microL; Curasan 1,140,500/microL) seemed to correlate with a higher level of TGF-beta1 (Spearman's correlation coefficient, r(s) = 0.7), whereas the higher leukocyte count in the Curasan PRP (PCCS 15,300/microL; Curasan 33,150/pL) had only a minor correlation with higher levels of PDGF-AB (r(s) = 0.46). DISCUSSION: The PCCS end product has both a higher platelet count and a higher total content of the growth factors investigated. Nevertheless, the biologic effect of the evaluated growth factor levels remains unknown. The amount of PRP necessary to achieve the intended biologic effects still remains unclear. CONCLUSION: PRP contains growth factors in high concentrations. Precise predictions of growth factor levels based on the thrombocyte counts of whole blood or PRP appeared limited. There are different sources for growth factors (platelets, leukocytes, plasma).